August 15, 2026 08:26 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Independence Day: PM Modi’s big youth pitch— AI training, free coaching amid exam row and job concerns | ‘Shakti Ki Saptadhara’: Modi reveals 7 pillars to power India’s next leap in his I-Day speech from Red Fort | West Bengal STF arrests 3 more suspected Pakistani spies in Cooch Behar | Bengal man arrested in Bengaluru over terror links, Afghanistan travel plan | Ajit Doval breaks silence on Operation Sindoor in Discovery’s explosive new docuseries | Rahul Gandhi's 'mock hug' taunt sparks row; Centre stresses 'mutual respect' with Italy | Delhi on high alert: Bomb threat to High Court, airport and multiple locations ahead of I-Day | ‘Who are they to interfere?’: CJI Surya Kant slams Bar Council of India over NALSAR students’ enrolment row | 'Shows how low Congress has sunk': BJP slams Rahul Gandhi over Modi foreign policy jibe | From guns to glamour: Former women Maoists walk the ramp in Chhattisgarh
Covaxin

Brazil denies permission to import Bharat Biotech developed Covaxin

| @indiablooms | Apr 01, 2021, at 04:41 am

New Delhi/IBNS:  Brazil's health regulator has denied permission to import Covaxin, the coronavirus vaccine developed by India's indigenous firm Bharat Biotech.

According to reports, a Brazilian government gazette had said that Covaxin had been rejected "considering the non-compliance with the requirements of Good Manufacturing Practices for Medicines''.

In its response to the same, Bharat Biotech has told NDTV: ''The requirements pointed out during inspection will be fulfilled, the timelines for fulfilment is under discussion with the Brazil NRA and will be resolved soon.''

Bharat Biotech's indigenous vaccine-Covaxin-has been developed in collaboration with the Indian Council for Medical Research.

It was approved for emergency use by the  Drugs Controller General of India (DCGI) in January.

Covaxin has been declared to be an 81 per cent success during the Phase 3 clinical trials in India. 

Bharat Biotech said the vaccine is effective against the UK variant of the virus.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.